Filtered By:
Condition: Hypertension
Procedure: Anesthesia
This page shows you your search results in order of date.
Order by Relevance | Date
Total 235 results found since Jan 2013.
Association of cervical atherosclerosis on Doppler ultrasonography and postoperative delirium in patients undergoing spinal surgery: a single-center, retrospective, observational study
CONCLUSIONS: There was a significant association between POD and the prevalence of cervical atherosclerosis using the univariate logistic regression analysis. Furthermore, multivariate logistic regression analyses showed that older age and antiplatelet agent use were independently associated with POD.PMID:37326838 | DOI:10.1007/s00586-023-07823-0
Source: Atherosclerosis - June 16, 2023 Category: Cardiology Authors: Gentaro Kumagai Kanichiro Wada Toru Asari Yohshiro Nitobe Hirotaka Kinoshita Tetsuya Kushikata Kazuyoshi Hirota Yasuyuki Ishibashi Source Type: research
Post-induction hypotension and intraoperative hypotension as potential separate risk factors for the adverse outcome: a cohort study
ConclusionsThe presence of IOH defined as MAP ≤ 65 mmHg is relevant to post-operative organ complications, the presence of PIH does not appear to be of such significance. Because cumulative duration of PIH and IOH differs significantly, especially in long-lasting procedures, direct comparison of the influence of PIH and IOH on outcome s eparately may be biased and should be taken into account in data interpretation. Further research is needed to deeply investigate this phenomenon.
Source: Journal of Anesthesia - April 21, 2023 Category: Anesthesiology Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Comparison of Nebulized Versus Intravenous Milrinone on Reducing Pulmonary Arterial Pressure in Patients with Pulmonary Hypertension Candidate for Open-cardiac Surgery: A Double-Blind Randomized Clinical Trial
CONCLUSIONS: Nebulized milrinone administration before weaning off cardiopulmonary bypass (CPB) can be accelerated and facilitate weaning off CPB. Moreover, despite maintaining MAP, nebulized milrinone significantly reduces mPAP. According to the results of this study, nebulized milrinone is recommended in patients undergoing cardiac surgery with pulmonary hypertension.PMID:36818483 | PMC:PMC9923341 | DOI:10.5812/aapm-122994
Source: Atherosclerosis - February 23, 2023 Category: Cardiology Authors: Sara Jorairahmadi Fatemeh Javaherforooshzadeh Marziyeh Babazadeh Behnam Gholizadeh Nima Bakhtiari Source Type: research
Combined Arterial Hypertension and Ischemic Stroke Exaggerate Anesthesia-Related Hypotension and Cerebral Oxygenation Deficits: A Preclinical Study
CONCLUSIONS: Our findings are the first demonstration that ischemic stroke per se increases the severity of IOH, particularly when combined with a prior history of hypertension; this combination appears to compromise penumbral perfusion.PMID:36730724 | DOI:10.1213/ANE.0000000000006263
Source: Anesthesia and Analgesia - February 2, 2023 Category: Anesthesiology Authors: Tracy Zhang Pratik Thakkar Tonja W Emans Debra Fong Suma Thampi Igor S A Felippe Carolyn J Barrett Robyn Billing Douglas Campbell Fiona D McBryde Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Outcomes of Carotid Stenting in Patients with Fibromuscular Dysplasia
CONCLUSION: Carotid artery stenting for fibromuscular dysplasia is a feasible and safe procedure with favorable technical success, low neurological complications, and good clinical outcomes at 1-year follow-up.PMID:36400362 | DOI:10.1016/j.jvs.2022.10.040
Source: Atherosclerosis - November 18, 2022 Category: Cardiology Authors: Jesus Porras-Colon Carla K Scott Alejandro Pizano Anna Driessen Carlos H Timaran John G Modrall Shirling Tsai Melissa L Kirkwood Bala Ramanan Source Type: research
Increased blood pressure variability during general anaesthesia is associated with worse outcomes after mechanical thrombectomy: a prospective observational cohort study
Conclusions
Increased intraprocedural BPV was more likely to have poor functional outcome in patients with LVO following MT with general anaesthesia. This finding indicates that special precautions should be taken to minimise BP fluctuation during procedure.
Source: BMJ Open - October 5, 2022 Category: General Medicine Authors: Xu, C., Jin, T., Chen, Z., Zhang, Z., Zhang, K., Mao, H., Ye, S., Geng, Y., Shi, Z. Tags: Open access, Neurology Source Type: research
E-030 Feasibility and safety of mechanical thrombectomy for sole primary angular artery M3 and M4 MCA occlusions
ConclusionAngular artery occlusions often present with disabling symptoms, commonly including speech deficits and limb paresis. Our limited data suggests that mechanical thrombectomy of the angular artery is feasible and safe. As with thrombectomy in other vascular territories, and amongst other factors, patient outcome is influenced by grade of reperfusion.Disclosures A. Kuhn: None. J. Singh: None. F. Massari: None. A. Puri: 1; C; NIH, Microvention, Cerenovus, Medtronic Neurovascular and Stryker Neurovascular. 2; C; Medtronic Neurovascular, Stryker NeurovascularBalt, Q’Apel Medical, Cerenovus, Microvention, Imperati...
Source: Journal of NeuroInterventional Surgery - July 23, 2022 Category: Neurosurgery Authors: Kuhn, A., Singh, J., Massari, F., Puri, A. Tags: SNIS 19th annual meeting electronic poster abstracts Source Type: research
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
